Penggunaan Deksametason pada Pasien COVID-19: Systematic Review dan Meta-analisis

Cut Ainul Mardhiyyah; Didik Setiawan; Binar Asrining Dhiani

doi:10.22435/jki.v13i1.5455

Cut Ainul Mardhiyyah Fakultas Farmasi Universitas YPIB, Majalengka, Indonesia
Didik Setiawan 2Program Magister Ilmu Farmasi, Fakultas Farmasi Universitas Muhammadiyah Purwokerto, Purwokerto, Indonesia
Binar Asrining Dhiani 2Program Magister Ilmu Farmasi, Fakultas Farmasi Universitas Muhammadiyah Purwokerto, Purwokerto, Indonesia

DOI: https://doi.org/10.22435/jki.v13i1.5455

Keywords: COVID-19, Dexamethasone, Corticosteroid, Meta-analysis, Systematic review

Abstract

COVID-19 is associated with disseminated lung damage in patients, Dexamethasone can reduce lung injury caused by inflammation and there reduce the progression to respiratory failure and prevent death. This systematic review aimed to determine the benefits and safety of Dexamethasone in COVID-19 treatment. The study was performed by a comprehensive literature search which were published in several databases i.e., PubMed, Science Direct, VHL Regional Portal, and ClinicalTrials.gov within the search time of 28 November 2020. Inclusion criteria were articles on the study on COVID-19 patients who received Dexamethasone, observational and experimental studies on the outcomes use evaluation of Dexamethasone. Exclusion criteria are the articles that do not provide control in controlled studies and do not show clear research results on the use of Dexamethasone. An initial search from four databases by entering keywords resulted in 1,046 articles. After screening articles duplication we obtained 835 studies. Finally, 6 articles were obtained after we screened for the article that it can be obtained its full text and 5 articles joined in articles included in the meta-analysis. The analysis showed that Dexamethasone in Covid-19 patients could reduce the incidence of death within 28 days with RR of 0.78 (95% CI 0.57–0.97 P=0.13) compared with Methylprednisolone, Dexamethasone was compared without corticosteroids with RR 0.89 (95% CI 0.82-0.97 P=0.01). Dexamethasone also reduced mechanical ventilator use during treatment with RR 0.95 (95% CI = 0.86-1.05 P = 0.28) compared without corticosteroids. The conclusion from these results: the use of Dexamethasone can reduce the number of deaths in COVID-19 patients, especially severe and critically ill category patients.

References

Singhal T. A Review of Coronavirus Disease-2019 (COVID-19). Indian J Pediatr. 2020;87:281–6.

Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427.

Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun [Internet]. 2020;109:102433.

Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693–704.

Yang Z, Liu J, Zhou Y, Zhao X, Zhao Q, Liu J. The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis. J Infect [Internet]. 2020;81:e13–20.

Garg AX, Hackam D, Tonelli M. Systematic review and meta-analysis: When one study is just not enough. Clin J Am Soc Nephrol. 2008;3:253–60.

Setiawan D, Luttjeboer J, Pouwels KB, Wilschut JC, Postma MJ. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: A meta-analysis. Jpn J Clin Oncol. 2017;47:265–76.

Siswanto. Systematic Review Sebagai Metode Penelitian Untuk Mensintasis Hasil-Hasil Penelitian (Sebuah Pengantar) (Systematic Review as a Research Method to Synthesize Research Results (An Introduction)). Bul Penelit Sist Kesehat. 2010;13:326–33.

Pati D, Lorusso LN. How to Write a Systematic Review of the Literature. Heal Environ Res Des J. 2018;11:15–30.

Rana MA, Hashmi M, Qayyum A, Pervaiz R, Saleem M, Munir MF, et al. Comparison of Efficacy of Dexamethasone and Methylprednisolone in Improving PaO2/FiO2 Ratio Among COVID-19 Patients. Cureus. 2020;12(10):e10918.

Carvallo HE, Hirsch RR, Farinella ME. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19 [Internet]. Available from: https://medrxiv.org/cgi/content/short/2020.09.10.20191619

Dheir H, Sipahi S, Yaylacı S, Çetin ES, Genç AB, Fırat N, et al. Clinical course of COVID-19 disease in immunosuppressed renal transplant patients. Turkish J Med Sci. 2021;51:428–34.

Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis 2020;20(11):276–88.

Bartoletti M, Marconi L, Scudeller L, Pancaldi L, Tedeschi S, Giannella M, et al. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study. Clin Microbiol Infect. 2021;27(1):105-11.

Organization WH. Corticosteroids for COVID-19: living guidance, 2 September 2020. World Health Organization; 2020.

Fatima SA, Asif M, Khan KA, Siddique N, Khan AZ. Comparison of efficacy of dexamethasone and methylprednisolone in moderate to severe covid 19 disease. Ann Med Surg. 2020;60:413–6.

Saha A, Ahsan MM, Quader TU, Shohan MUS, Naher S, Dutta P, et al. Characteristics, management and outcomes of critically ill COVID-19 patients admitted to ICU in hospitals in Bangladesh: a retrospective study. Journal of preventive medicine and hygiene. 2021;62(1):e33.

Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial. JAMA. 2020;324:1307–16.

Singh AK, Majumdar S, Singh R, Misra A. Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician’s perspective. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):971–8.

Tlayjeh H, Mhish OH, Enani MA, Alruwaili A, Tleyjeh R, Thalib L, et al. Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. J Infect Public Health. 2020;13(11):1652-63.

Sterne JAC, Murthy S, Diaz J V, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with covid-19. JAMA. 2020;324(13):1330-1341.

Villar J, Añón JM, Ferrando C, Aguilar G, Muñoz T, Ferreres J, et al. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. Trials. 2020;21(1):1-10.

Maskin LP, Olarte GL, Palizas FJ, Velo AE, Lurbet MF, Bonelli I, et al. High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):1-3.

Rubio-Rivas M, Ronda M, Padulles A, Mitjavila F, Riera-Mestre A, Garcia-Forero C, et al. Beneficial Effect of Corticosteroids in Preventing Mortality in Patients Receiving Tocilizumab to Treat Severe COVID-19 Illness. International Journal of Infectious Diseases, 2020;101: 290-97.